
[2-(2-dimethylaminoethyl)-5-(4-methoxyphenyl)-3-oxo-6-thia-2- azabicyclo[5.4.0]undeca-7,9,11-trien-4-yl]ethanoate
1.陣發性上室性心搏過速,對於心房撲動、心房纖維顫動情況時,快遠心室心搏之暫時性控制。通常成人1次Diltiazem HCl 10mg徐緩靜脈注射約3分鐘。依年齡、症狀適宜增減用量。
2.緊急性高血壓:通常成人每分鐘投與5-15μg/kg b.w.之輸注量,需利用靜脈點滴給藥,當血壓降至目標值之後,需監測血壓值,來調整輸注速率。
Absorption
IV
T max is 2 to 3 h.
Extended release (ER)
T max is 10 to 14 h.
Immediate release (IR)
T max is 2 to 4 h.
Distribution
Vd approximately 305 L. 70% to 80% protein bound (approximately 40% to α l -acid glycoprotein and approximately 30% to albumin). Excreted in breast milk.
Metabolism
Metabolized in the liver (including via CYP-450) to several metabolites; desacetyl diltiazem is 25% to 50% as potent as diltiazem. Undergoes first-pass metabolism after oral administration.
Elimination
The t ½ is approximately 3.4 h (IV), 4 to 9 h (ER), and 3 to 4.5 h (IR). 2% to 4% excreted unchanged in urine (oral). Systemic Cl approximately 65 L/h (IV).
Peak
2 to 5 min (IV).
Special Populations
Hepatic Function Impairment
Bioavailability is increased, and t ½ is prolonged.
Anesthetics
Depression of cardiac contractility, conductivity, and automaticity as well as vascular dilation associated with anesthetics may be potentiated.
Benzodiazepines (eg, midazolam, triazolam), carbamazepine, cyclosporine, digitalis, encainide, lovastatin
Plasma levels of these agents may be elevated by diltiazem, increasing the pharmacologic and toxic effects.
Beta-blockers
May have additive negative inotropic and chronotropic effects.
Cimetidine, ranitidine
Diltiazem levels may be increased.
Other antihypertensive agents
May have additive effects.
Rifampin
Coadministration lowered diltiazem plasma concentrations to undetectable levels.
2.第二度以上房室傳導阻斷患者,有竇性不全症候群(持續性之竇性脈搏徐緩 (<5O次/分)、竇性休止、費房傳導阻斷等)之患者。
(可能使本劑之心臟刺激生成抑制作用,心傅導抑制作用的情形過度出現)
3.嚴重鬱血性心不全者。(鬱血性心不全症狀可能惡化)
4.嚴重心肌症患者。(鬱血性心不全症狀可能惡化)
5.對本劑過敏的患者。
6.孕婦或可能懷孕的婦女。
2.當需要使用本藥在可能會發生完房室阻。
過量投與會出現脈搏徐緩、完全房室阻斷、心不全、低血壓等症狀。但是也有報告將這些症狀當作副作用的。
◎處置:
過量投與時,應中止投與本劑,並進行下列之過當處置。
1.脈搏徐緩、完全房室阻斷:
可投與atropine sulfate、isoproterenol等,及視需要進行心臟整律(pacing)等之適當處置。
2.心不全、低血壓:
可投與強心劑、昇壓劑、輸注液等,並採用輔助循環之處置。



